A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours
{{output}}
Background: Trastuzumab brengitecan (T-Bren; BL-M07D1) is a HER2-directed antibody-drug conjugate (ADC) comprising a monoclonal antibody, a cathepsin B-cleavable linker, and a potent topoisomerase I inhibitor payload (Ed-04). We ... ...
